Medical Research
About
The John Curtin School of Medical Research is amongst Australia's leading research institutes and performs fundamental research that tackles real-world health challenges whilst nurturing the next generation of medical researchers.
The institute was established in 1948 as a founding school of the Australian National University. We are renowned for pioneering medical breakthroughs. With a legacy of three Nobel Laureates and a league of exceptional researchers, our focus is collaborative, innovative research tackling diseases that encompass cancer, infectious diseases and neurological conditions using our expertise in neuroscience, genomics, immunology, and cancer discovery science.
Facilities
The Advanced Imaging Precinct includes the Centre for Advanced Microscopy (CAM) and the National Laboratory for X-ray Micro Computed Tomography (CTLab).
The ANU Centre for Therapeutic Discovery (ACTD) is a state-of-the-art high-throughput screening facility for biomarker and therapeutic discovery.
We are committed to helping researchers be at the forefront of scientific discovery in the fields of genetics, genomics, and molecular biosciences.
The CHASM Facility offers cutting edge instrumentation and expertise in high dimensional flow cytometry cell analysis, cell sorting, histology, automated immunochemistry, in vivo optical imaging, low dose micro-CT and Spatial Multiomics services.
The National Therapeutic mRNA Platform (NTRP) is an open-access sovereign platform for the design, testing and optimisation of novel therapeutic mRNA candidates.
News
Emerging researchers from ANU have been selected in the 2025 CHARM Rising Star Awards, celebrating their outstanding early-career impact in health research and innovation in the ACT.
A world-first clinical trial targeting cancers that are currently undruggable will begin later this year, led by a research team from The Australian National University (ANU) and Canberra Health Services.
These scientists can 3D-print living cells – a first step to printing our own organs.
A potent opioid detected in Canberra for the first time in September 2024 carries a high risk of overdose, warn chemists from the ANU and drug checking service CanTEST.
Artificial intelligence (AI)-powered protein models combined with genome sequencing technology could help scientists better diagnose and treat genetic diseases.
Scientists from all over the world have been racing to understand the fundamentals of Devil Facial Tumour Disease and find a way to stop it. One of them is Yi Ning (Sabrina) Fu, a recent Honours graduate at JCSMR.